IN3BIO gains approval for Phase I/II clinical trial
10 June 2021 | Thursday | News
IN3BIO Research Limited announced today that the company has received the Clinical Trial Application approval from the Bulgarian Drug Agency and Ethical Committee to initiate a Phase I/II clinical trial of its colorectal cancer vaccine in Bulgaria.
IN3BIO will trial its innovative anti-EGF vaccine IN01, in combination with small molecule inhibitors (SMIs) in patients suffering from KRAS or NRAS (Cohort A) or BRAF (Cohort B) mutated colorectal cancer.
Erik D'Hondt, CEO of IN3BIO said "We are delighted to have reached this significant regulatory step to conduct our clinical trial in Bulgaria. This first approval will lead to patients being enrolled rapidly in centres in Bulgaria, then in clinical centres in other EU and non-EU countries".
Most Read
- Biotech and Biopharma Industry Trends: What to Watch for in 2024
- Revolutionizing Drug Discovery: 15 AI Companies to Watch in 2024
- Pioneering Precision: Top 15 Clinical and Lab Diagnostic Companies to Watch in 2024
- 2024's Biopharma Roadmap: Top 24 Biopharma Trends to Watch in 2024
- Breakthroughs Unveiled: A Year of Groundbreaking Novel Drug Approvals in 2023
- Revolutionizing Tomorrow: Top 24 Emerging Biotech Innovations to Watch in 2024
Bio Jobs
- Leica Microsystems Announces Vacancy for Senior Imaging FPGA Testing Engineer in Singapore
- Glen Godresse Takes Helm as CEO of Menarini Asia-Pacific
- Eva van Pelt Joins Qiagen's Supervisory Board, Bringing a Wealth of Global Leadership Experience in Healthcare and Life Sciences
- Life Sciences Queensland Welcomes Dr. Kym Baker and Dr. Denise Hodge to Board Leadership
- Bayer appoints Nelson Ambrogio as new Head of Radiology Business at Pharmaceuticals Division
- Danaher Careers - Search Global Science and Technology Jobs
- Careers at MERCK Group
- Ajinomoto Bio-Pharma Services Announces Leadership Changes at US Facility
- Veranova Appoints Mike Riley as Chief Executive Officer
- Find your Job at Eppendorf
News
Editor Picks
